Comparison of glucose control by added liraglutide to only insulin infusion in DM patient undergoing cardiac surgery: A randomized-controlled trial

Phase 2

Completed

• Conditions: Glycemic variability in diabetic patients who undergo the cardiac surgery; Glycemic Variability: GV = Coefficient of variation = standard deviation/mean; Liraglutide Drug = VictozaTM; Continuous glucose monitoring = IPro2; Medtronic

• Registration Number: TCTR20190118012
• Lead Sponsor: Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-01-04
• Study Start: 2019-01-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Diabetic patients who undergo coronary artery bypass graft operation or valvular surgery that use cardiopulmonary bypass

Exclusion Criteria

1.History allergy to Liraglutide or insulin drug
2.Patients have contraindication for using Liraglutide drug such as Medullary thyroid carcinoma, Multiple Endocrine Neoplasia Syndrome type2(MEN type2), Thyroid C-cell tumors and Pancreatitis
3.Patients have Diabetic Ketoacidosis condition during reseach progression.
4.Patientds have allergic reaction to liraglutide drug during reseach progression.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The effect of Liraglutide on glycemic variability in cardiac surgery Intraoperative and Postoperative periods Glycemic Variability = Coefficient of variation = standard deviation/mean glucose level of patients

Secondary Outcome Measures

Name	Time	Method
Effect of Liraglutide for reduction of insulin usage on blood glucose control in cardiac surgery Intraoperative and Postoperative periods Evalutation dose of insulin usage between Liraglutide added with insulin and insulin only groups